A Prospective, Assessor-blind, Randomized, Parallel group Clinical Trial to Assess Single Dose Pharmacokinetics and Pharmacodynamics of Inj. Romiplostim from Intas Pharmaceuticals Ltd. and Inj. Romiplostim of Amgen Inc. in Patients with Chronic Refractory Immune (Idiopathic) Thrombocytopenic Purpura - NA
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Pharmacokinetics
- Sponsors Intas Pharmaceuticals
- 30 Apr 2018 Status changed from not yet recruiting to recruiting.
- 04 Jan 2018 New trial record